Literature DB >> 26563871

Genomic Correlates to the Newly Proposed Grading Prognostic Groups for Prostate Cancer.

Mark A Rubin1, Gabriele Girelli2, Francesca Demichelis3.   

Abstract

UNLABELLED: Recommendations by the International Society of Urologic Pathology and 2016 World Health Organization blue book propose the use of a five-tiered prostate cancer (PCa) grading system. The five prognostic grade groupings (PGGs) ranging from 1 to 5 are defined as Gleason grades ≤ 6, 3 + 4, 4 + 3, 8, and > 8, respectively. Recent work suggests that each group is associated with a distinct risk of biochemical PCa recurrence. In this study, we sought genomic support for PGGs using whole-exome and whole-genome sequencing data for 426 clinically localized PCas treated by radical prostatectomy. After adjustment for tumor purity for the sequencing data, we observed a significant frequency increase in genomic amplifications and deletions (p = 0.013) and in nonsynonymous point mutations (p = 0.008) with increasing risk group. Interestingly, PGG1 (low risk) was entirely haploid, whereas PGG2-5 exhibited increasing polyploidy frequency. Principal component analysis of genomic profiles revealed that PGG1, PGG2, and PGG3 represent distinct classes, but PGG4 and PGG5 exhibit genomic similarity. Together, these observations for the largest PCa genomic data set to date provide support for increasing genomic alterations with increasing PGG. This is the first genomic correlation of the PGG system. Future work will need to explore the clinical utility of PGGs in prospective studies with long-term follow-up. PATIENT
SUMMARY: Gleason grading for prostate cancer provides important information for guiding clinical care. A new proposal by leading pathologists favors translating Gleason grades into five risk categories. In this study, a comprehensive analysis of the largest genomic data set on prostate cancer to date, we demonstrate molecular support for this new five-tiered system.
Copyright © 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Active surveillance; Genomics; Gleason grading; Precision medicine; Prostate cancer; Risk

Mesh:

Substances:

Year:  2015        PMID: 26563871     DOI: 10.1016/j.eururo.2015.10.040

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  17 in total

Review 1.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

2.  The Landscape of Whole-genome Alterations and Pathologic Features in Genitourinary Malignancies: An Analysis of the Cancer Genome Atlas.

Authors:  Mark W Ball; Michael A Gorin; Charles G Drake; Hans J Hammers; Mohamad E Allaf
Journal:  Eur Urol Focus       Date:  2017-02-08

Review 3.  Genomic and phenotypic heterogeneity in prostate cancer.

Authors:  Michael C Haffner; Wilbert Zwart; Martine P Roudier; Lawrence D True; William G Nelson; Jonathan I Epstein; Angelo M De Marzo; Peter S Nelson; Srinivasan Yegnasubramanian
Journal:  Nat Rev Urol       Date:  2020-12-16       Impact factor: 14.432

Review 4.  Somatic Mutations in Prostate Cancer: Closer to Personalized Medicine.

Authors:  M J Alvarez-Cubero; L J Martinez-Gonzalez; I Robles-Fernandez; J Martinez-Herrera; G Garcia-Rodriguez; M Pascual-Geler; J M Cozar; J A Lorente
Journal:  Mol Diagn Ther       Date:  2017-04       Impact factor: 4.074

Review 5.  Histopathology of Prostate Cancer.

Authors:  Peter A Humphrey
Journal:  Cold Spring Harb Perspect Med       Date:  2017-10-03       Impact factor: 6.915

Review 6.  Targeting treatment options for castration-resistant prostate cancer.

Authors:  Dannah R Miller; Matthew A Ingersoll; Benjamin A Teply; Ming-Fong Lin
Journal:  Am J Clin Exp Urol       Date:  2021-02-15

7.  Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy.

Authors:  David J VanderWeele; Richard Finney; Kotoe Katayama; Marc Gillard; Gladell Paner; Seiya Imoto; Rui Yamaguchi; David Wheeler; Justin Lack; Maggie Cam; Andrea Pontier; Yen Thi Minh Nguyen; Kazuhiro Maejima; Aya Sasaki-Oku; Kaoru Nakano; Hiroko Tanaka; Donald Vander Griend; Michiaki Kubo; Mark J Ratain; Satoru Miyano; Hidewaki Nakagawa
Journal:  Eur Urol Focus       Date:  2018-02-15

Review 8.  Newly Proposed Prognostic Grade Group System for Prostate Cancer: Genesis, Utility and its Implications in Clinical Practice.

Authors:  Makarand Khochikar
Journal:  Curr Urol Rep       Date:  2016-11       Impact factor: 3.092

Review 9.  The Genomics of Prostate Cancer: A Historic Perspective.

Authors:  Mark A Rubin; Francesca Demichelis
Journal:  Cold Spring Harb Perspect Med       Date:  2019-03-01       Impact factor: 6.915

10.  Aneuploidy drives lethal progression in prostate cancer.

Authors:  Konrad H Stopsack; Charles A Whittaker; Travis A Gerke; Massimo Loda; Philip W Kantoff; Lorelei A Mucci; Angelika Amon
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.